Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list

PURPOSE: To assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China’s 2020 National Reimbursement Drug List (NRDL). METHODS: A comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs listed in Ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liu, Jiang, Zhixin, Li, Fuming, Wei, Yan, Ming, Jian, Yang, Yi, Liu, Shimeng, Shi, Lizheng, Chen, Yingyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719239/
https://www.ncbi.nlm.nih.gov/pubmed/36463141
http://dx.doi.org/10.1186/s12913-022-08858-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719239/
https://www.ncbi.nlm.nih.gov/pubmed/36463141
http://dx.doi.org/10.1186/s12913-022-08858-7

Ejemplares similares